Business Context and Reporting Period
This Form 8-K Current Report was filed by Agios Pharmaceuticals, Inc. on July 3, 2025. The report discloses corporate governance changes, specifically the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and appointment details.
Material Changes
The primary material change reported is the election of Jay Backstrom, M.D., MPH, to the Board of Directors, effective July 8, 2025. Dr. Backstrom has been designated as a Class III director and appointed to the Science and Technology Committee.
Compensatory Arrangements and Governance
- Cash Compensation: Dr. Backstrom will receive an annual cash retainer of $50,000 for board service and an additional $7,500 annually for committee service.
- Equity Grants:
- A nonstatutory stock option with a Black-Scholes value of $472,500, vesting 25% on the first anniversary and the remainder over 36 months.
- Restricted stock units (RSUs) valued at $157,500, vesting in equal thirds over three years.
- Indemnification: Dr. Backstrom will enter into an indemnification agreement covering expenses, judgments, fines, and settlement amounts related to his service.
Investor Verification Checklist
- Verify the closing price of AGIO common stock on July 8, 2025, to calculate the exact number of shares granted under the stock option and RSU awards.
- Review the full text of the Indemnification Agreement referenced in Exhibit 10.12 of the Company's 2013 Form S-1.
- Confirm Dr. Backstrom's background and potential conflicts of interest, noting the filing states no transactions requiring disclosure under Item 404(a) currently exist.